<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38708693</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2150-1327</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Journal of primary care &amp; community health</Title><ISOAbbreviation>J Prim Care Community Health</ISOAbbreviation></Journal><ArticleTitle>Determination of COVID-19 Late Disorders as Possible Long-COVID and/or Vaccination Consequences.</ArticleTitle><Pagination><StartPage>21501319241251941</StartPage><MedlinePgn>21501319241251941</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">21501319241251941</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/21501319241251941</ELocationID><Abstract><AbstractText>In this era in which the vast majority of the global population have developed COVID-19 infection and/or got vaccinated against it, identification of the late disorders as the vaccines' side effect or long-COVID manifestation seems essential. This study included the vaccinated individuals of 4 different vaccine regimens including inactivated virus-based, subunit protein, and adenovirus-based vaccines in a follow-up schedule 6-month post the booster shot. All the documented vaccine adverse events were thoroughly assessed considering the cases' medical history by Adverse Events Committee of Pasteur Institute of Iran. Totally 329 individuals who got 3 doses of vaccination were followed 6&#x2009;months after the booster shots among whom 41 (12.4%) cases with the mean age of 40.9&#x2009;&#xb1;&#x2009;10.48&#x2009;years had a type of disorder. Gynecological and osteoarticular involvements were the most common recorded disorders of which 73.1% were possibly linked to vaccination outcomes and the rest were affected by both long-COVID-19 and vaccination. Notably, the average time of symptoms persistence was 155&#x2009;&#xb1;&#x2009;10.4&#x2009;days. This study has the advantage of long-term follow-up which presents various forms of late events in each episode of COVID-19 infection and vaccination. About 26.8% of people with persistent complications suffered from both long-COVOD/ vaccination in whom the differentiation between the vaccine side effect and long-COVID manifestation was quite challenging. Long-term follow-up studies in large population seems essential to outline the role of long-COVID and vaccination regarding persistent complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sadat Larijani</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bavand</LastName><ForeName>Anahita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banifazl</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Iranian Society for Support of Patients With Infectious Disease, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashrafian</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moradi</LastName><ForeName>Ladan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramezani</LastName><ForeName>Amitis</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3502-8524</Identifier><AffiliationInfo><Affiliation>Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Prim Care Community Health</MedlineTA><NlmUniqueID>101518419</NlmUniqueID><ISSNLinking>2150-1319</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">late AEs</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">long-VAX</Keyword><Keyword MajorTopicYN="N">long-term disorders</Keyword><Keyword MajorTopicYN="N">vaccine outcome</Keyword></KeywordList><CoiStatement>Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>6</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38708693</ArticleId><ArticleId IdType="pmc">PMC11075438</ArticleId><ArticleId IdType="doi">10.1177/21501319241251941</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Srikanth S, Boulos JR, Dover T, Boccuto L, Dean D. Identification and diagnosis of long COVID-19: a scoping review. Prog Biophys Mol Biol. 2023;182:1-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10176974</ArticleId><ArticleId IdType="pubmed">37182545</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Post COVID-19 Condition (Long COVID). WHO;2022.</Citation></Reference><Reference><Citation>van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39(1):159-167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadat Larijani M, Doroud D, Banifazl M, et al. A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports. Eur J Med Res. 2023;28(1):542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10676592</ArticleId><ArticleId IdType="pubmed">38008729</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourrazavi S, Fathifar Z, Sharma M, Allahverdipour H. COVID-19 vaccine hesitancy: a systematic review of cognitive determinants. Health Promot Perspect. 2023;13(1):21-35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10257562</ArticleId><ArticleId IdType="pubmed">37309435</ArticleId></ArticleIdList></Reference><Reference><Citation>Duradoni M, Gursesli MC, Materassi L, Serritella E, Guazzini A. The long-COVID experience changed people&#x2019;s vaccine hesitancy but not their vaccination fear. Int J Environ Res Public Health. 2022;19(21):14550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9654193</ArticleId><ArticleId IdType="pubmed">36361430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: vaccinated people are less likely to get long covid, review finds. BMJ. 2022;376:o407.</Citation><ArticleIdList><ArticleId IdType="pubmed">35172970</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul K, Gorelik Y, Zayyad H, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. NPJ Vaccines. 2022;7(1):101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine. 2022;53:101624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Ortega-Santiago R, Fuensalida-Novo S, Mart&#xed;n-Guerrero JD, Pellicer-Valero OJ, Torres-Macho J. Differences in long-COVID symptoms between vaccinated and non-vaccinated (BNT162b2 vaccine) hospitalized COVID-19 survivors infected with the delta variant. Vaccines. 2022;10:1481. doi:10.3390/vaccines10091481</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10091481</ArticleId><ArticleId IdType="pmc">PMC9504977</ArticleId><ArticleId IdType="pubmed">36146560</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadat Larijani M, Sorouri R, Eybpoosh S, et al. Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study. Pathog Dis. 2023;81:ftad010.</Citation><ArticleIdList><ArticleId IdType="pubmed">37230943</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramezani A, et al. PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals. Sci. Rep. 2023;13(1):8065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10195798</ArticleId><ArticleId IdType="pubmed">37202438</ArticleId></ArticleIdList></Reference><Reference><Citation>Eybpoosh S, Biglari A, Sorouri R, et al. Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals. PLOS Pathog. 2023;19(11):e1011744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10619776</ArticleId><ArticleId IdType="pubmed">37910480</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. A case report: long post-COVID vaccination syndrome during the eleven months after the third moderna dose. Cureus. 2022;14(12):e32433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9833629</ArticleId><ArticleId IdType="pubmed">36644105</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohidi F, Sadat SM, Bolhassani A, Yaghobi R, Larijani MS. Induction of a robust humoral response using HIV-1 VLP(MPER-V3) as a novel candidate vaccine in BALB/c mice. Curr HIV Res. 2019;17(1):33-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">30843489</ArticleId></ArticleIdList></Reference><Reference><Citation>Larijani MS, Ramezani A, Mashhadi Abolghasem Shirazi M, et al. Evaluation of transduced dendritic cells expressing HIV-1 p24-Nef antigens in HIV-specific cytotoxic T cells induction as a therapeutic candidate vaccine. Virus Res. 2021;298:198403.</Citation><ArticleIdList><ArticleId IdType="pubmed">33775753</ArticleId></ArticleIdList></Reference><Reference><Citation>Larijani MS, Pouriayevali MH, Sadat SM, Ramezani A. Production of recombinant HIV-1 p24-Nef protein in two forms as potential candidate vaccines in three vehicles. Curr Drug Deliv. 2020;17(5):387-395.</Citation><ArticleIdList><ArticleId IdType="pubmed">32183667</ArticleId></ArticleIdList></Reference><Reference><Citation>Finterer J, Scorza FA. A retrospective analysis of clinically confirmed long post-COVID vaccination syndrome. J Clin Transl Res. 2022;8(6):506-508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9706319</ArticleId><ArticleId IdType="pubmed">36452006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur U, Bala S, Joshi A, et al. Persistent health issues, adverse events, and effectiveness of vaccines during the second wave of COVID-19: a cohort study from a tertiary hospital in North India. Vaccines (Basel). 2022;10(7):1153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9319407</ArticleId><ArticleId IdType="pubmed">35891317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022;377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadat Larijani M, Banifazl M, Karami A, Ramezani A. Long-term rheumatoid manifestations as a consequence of COVID-19 and/or vaccination: a case report after a 2-year follow-up. Heliyon. 2024;10(3):e24982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10840001</ArticleId><ArticleId IdType="pubmed">38317942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur U, Fatima Z, Maheshwari K, et al. Long-term safety analysis of the ChAdOx1-nCoV-19 corona virus vaccine: results from a prospective observational study in priority vaccinated groups in North India. Drug Saf. 2023;46(6):553-563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10155654</ArticleId><ArticleId IdType="pubmed">37133805</ArticleId></ArticleIdList></Reference><Reference><Citation>Naguib R. Potential relationships between COVID-19 and the thyroid gland: an update. J Int Med Res. 2022;50(2):3000605221082898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8894980</ArticleId><ArticleId IdType="pubmed">35226548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>